IP Library Granted Patent US 11,510,951
Granted Patent B2
US 11,510,951 · App. 16/805,512 · Granted Nov 29, 2022

Hemp pomace co-fermented with mycelia to form a dietary supplement

Inventor: Jordan Seth Rubin (College Grove, TN)
Assignee: Fermented Farmer, LLC
A61K36/06A61K9/14A61K9/20A61K9/48A61K31/05A61K31/352A61K36/185A61K2236/17A61K2236/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,510,951
App. No.
16/805,512
Granted
Nov 29, 2022
Kind
B2
Abstract

The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace that has been co-fermented with a complex fungi, compounded as a tablet or formulated within a capsule. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of at least one part soluble dietary fiber to 30 parts insoluble dietary fiber, and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Claims (5)

1. A cannabinoid oral dosage form in unit dosage form, consisting essentially of hemp pomace, said hemp pomace further comprising spent extracted hemp biomass, co-fermented with a fungus selected from the group consisting of Ganoderma lucidum, Ganoderma japonicum, Ganoderma applanatum, Ganoderma Tsugae, Lentinula edodes, Grifola frondosus, Tremella fuciformia, Tremella mesenterica, Cordyceps sinensis, Cordyceps militaris, Hericium erinaceus, Polyporous umbellatus, Scizophylum commune, Fomes fomentaris, Inonotuus obliquus, Lepiota procera, Auricularia auricula, Tuber melanosporum, Tricholoma matsutake, Hericium coralloides, Trametes versicolor, Phellinus linteus, Poria cocos, Antrodia camphorata, Flammulina velutipes, Pleurotus ostreatus, Pleurotus energyii , and Agaricus blazeii , compounded as a tablet or within a capsule or powder dosage form and having a maximum cannabinoid dose per unit dosage form of 25 mg.

2. The cannabinoid oral dosage form in unit dosage form according to claim 1 , wherein said hemp pomace contains cannabinoids including cannabidiol (CBD), cannabigerol (CBG) and tetrahydrocannabinol (THC) and further having a ratio of CBD or CBG to THC of between 60:1-120:1.

3. The oral dosage form of claim 1 , wherein each oral dosage form contains less than 10 % water as moisture and wherein said cannabinoid is one or more of cannabidiol, cannabigerol, cannabidivarin, cannabichromene, or cannabinol.

4. The oral dosage form of claim 1 , wherein said hemp pomace co-fermented with said fungus is compounded as one or more tablets or capsules without separation of the hemp pomace or the co-fermentation products.

5. The oral dosage form of claim 1 , wherein said dosage form contains no more than 10 mg cannabinoid per unit dosage form.

Assignments (2)
CHANGE OF NAME Recorded Sep 9, 2021
From: BEYOND HEMP, LLC
To: FERMENTED FARMER, LLC
Reel/Frame 057453/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2020
From: RUBIN, JORDAN SETH
To: BEYOND HEMP, LLC
Reel/Frame 052098/0358 →
Continuity (2)
Provisional Application 62912930 · Oct 9, 2019
Related Publication 20210106635A1 · Apr 15, 2021